stoxline Quote Chart Rank Option Currency Glossary
Paratek Pharmaceuticals, Inc. (PRTK)
2.23  0.04 (1.83%)    09-20 16:00
Open: 2.19
High: 2.24
Volume: 4,476,125
Pre. Close: 2.19
Low: 2.19
Market Cap: 128(M)
Technical analysis
2023-10-20 4:25:52 PM
Short term     
Mid term     
Targets 6-month :  2.61 1-year :  3.05
Resists First :  2.24 Second :  2.61
Pivot price 2.21
Supports First :  2.2 Second :  2.18
MAs MA(5) :  2.23 MA(20) :  2.21
MA(100) :  2.12 MA(250) :  2.18
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  83.3 D(3) :  83.3
RSI RSI(14): 59.1
52-week High :  3.65 Low :  1.28
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ PRTK ] has closed below upper band by 28.4%. Bollinger Bands are 71.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 69 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.24 - 2.25 2.25 - 2.26
Low: 2.2 - 2.21 2.21 - 2.23
Close: 2.21 - 2.23 2.23 - 2.25
Company Description

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

Headline News

Tue, 19 Sep 2023
Is Paratek Pharmaceuticals Inc (PRTK) a Winner in the Biotechnology Industry? - InvestorsObserver

Tue, 19 Sep 2023
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) is definitely on the radar of institutional investors who own 48% of the ... - Yahoo Finance

Wed, 09 Aug 2023
Investor Alert: Abbott Cooper PLLC Announces Investigation into Paratek Pharmaceuticals, Inc.; Urges Paratek ... - Business Wire

Sun, 11 Jun 2023
PRTK Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Paratek Pharmaceuticals, Inc. Is Fair to ... - Business Wire

Tue, 06 Jun 2023
Paratek Pharmaceuticals (PRTK) to be Acquired by Gurnet Point Capital and Novo Holdings -

Mon, 15 May 2023
Paratek Pharmaceuticals (NASDAQ:PRTK) investors are sitting on a loss of 83% if they invested five years ago - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 57 (M)
Shares Float 50 (M)
Held by Insiders 11.6 (%)
Held by Institutions 55 (%)
Shares Short 2,640 (K)
Shares Short P.Month 2,910 (K)
Stock Financials
EPS -1.12
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -3.52
Profit Margin -35.5 %
Operating Margin -25.2 %
Return on Assets (ttm) -18 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 34.9 %
Gross Profit (p.s.) 1.73
Sales Per Share 3.08
EBITDA (p.s.) -0.78
Qtrly Earnings Growth 0 %
Operating Cash Flow -23 (M)
Levered Free Cash Flow -24 (M)
Stock Valuations
PE Ratio -2.01
PEG Ratio 0
Price to Book value -0.64
Price to Sales 0.72
Price to Cash Flow -5.51
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android